IP Library › Granted Patent US 12,285,738
Granted Patent B2
US 12,285,738 · App. 17/401,179 · Granted Apr 29, 2025

Modulation of glucose bioaccessibility with superabsorbent materials

Inventor: Lijun Sun (La Canada Flintridge, CA)
B01J20/24A61K31/736B01J20/3021B01J20/3078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,738
App. No.
17/401,179
Granted
Apr 29, 2025
Kind
B2
Abstract

A treatment for reducing glucose bioaccessibility can include providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together. The superabsorbent material can be administered to a subject in an effective amount to reduce glucose bioaccessibility in the subject. In some aspects, the treatment for reducing glucose bioaccessibility with the superabsorbent material retains a substantially unaltered fatty acid bioaccessibility and/or retains a substantially unaltered protein bioaccessibility.

Claims (20)

1. A method for reducing glucose bioaccessibility in a subject, comprising administering to the subject an effective amount of a superabsorbent material having a porous network structure without any chemical cross-linking; wherein the superabsorbent material is a dehydrated gel comprising agar, carrageenan, and konjac gum; and wherein the superabsorbent material has an absorption ratio of at least 10 in deionized water at 25° C.

2. The method of claim 1 , wherein

the superabsorbent material is administered before, during, or after the subject has consumed a glucose-containing food or a glucose-generating food.

3. The method of claim 2 , wherein the superabsorbent material is administered in an amount from about 0.01% to about 20% by weight of the consumed food.

4. The method of claim 1 , wherein the superabsorbent material has an average particle size of from about 0.1 micron to 1 mm.

5. The method of claim 1 , wherein the superabsorbent material is administered in an amount from about 0.1 g to about 20 g per dose.

6. The method of claim 2 , wherein the glucose-generating food is a carbohydrate.

7. The method of claim 1 , wherein the glucose bioaccessibility is reduced with the superabsorbent material compared to the glucose bioaccessibility without the superabsorbent material.

8. The method of claim 2 , wherein the glucose bioaccessibility is reduced with the superabsorbent material compared to the glucose bioaccessibility without the superabsorbent material after about 60 minutes after the consumption of the food.

9. The method of claim 8 , wherein the glucose bioaccessibility is reduced with the superabsorbent material compared to the glucose bioaccessibility without the superabsorbent material before about 140 minutes after the consumption of the food.

10. The method of claim 1 , wherein the method is to inhibit an increase or reduce at least one of: the weight of the subject; fat in the subject; or a fatty liver disease in the subject.

11. The method of claim 1 , wherein the method is to inhibit an increase or reduce at least one of: total cholesterol in the subject; low-density lipoprotein (LDL) in the subject; or high-density lipoprotein (HDL) in the subject.

12. The method of claim 1 , wherein the method is to inhibit an increase or reduce at least one of: fasting insulin level in the subject; fasting leptin level in the subject; or a HOMA-IR value for the subject.

13. The method of claim 1 , wherein the superabsorbent material comprises at least 10% by weight of agar.

14. The method of claim 1 , wherein the superabsorbent material comprises at least 20% by weight of carrageenan.

15. The method of claim 1 , wherein the superabsorbent material comprises agar, carrageenan, and konjac gum at a weight ratio of 10:1:1, 1:1:1, 1:1:2, 1:2:1, 2:1:1, or 2:5:5.

16. The method of claim 1 , wherein the superabsorbent material comprises agar, carrageenan, and konjac gum at a weight ratio of 1:1:1, 1:1:2, or 1:2:1.

17. The method of claim 1 , wherein the superabsorbent material has an absorption ratio from 20 to 200 in deionized water at 25° C.

18. The method of claim 1 , wherein the superabsorbent material has an absorption ratio from 50 to 200 in deionized water at 25° C.

19. The method of claim 1 , wherein the superabsorbent material has an absorption ratio from 100 to 200 in deionized water at 25° C.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2024
From: SIMEON INVESTMENT, INC.
To: ETERNAL SUNRISE TRUST
Reel/Frame 066553/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2022
From: HEALTHALL LABORATORY, INC.
To: SIMEON INVESTMENT, INC.
Reel/Frame 060971/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2021
From: SUN, LIJUN
To: HEALTHALL LABORATORY, INC.
Reel/Frame 057182/0064 →
Continuity (5)
Continuation In Part 17339416 · Jun 4, 2021
Division 16807004 · Mar 2, 2020
Continuation PCTUS2019046077 · Aug 10, 2019
Provisional Application 62717644 · Aug 10, 2018
Related Publication 20210370269A1 · Dec 2, 2021
References Cited (74)
US 4781838A · Crassous et al. · 1988 [cited by applicant]
US 5409703A · McAnalley et al. · 1995 [cited by applicant]
US 5545414A · Behr et al. · 1996 [cited by applicant]
US 6271278B1 · Park et al. · 2001 [cited by applicant]
US 7157431B2 · McAnalley et al. · 2007 [cited by applicant]
US 8128977B2 · Anfinsen et al. · 2012 [cited by applicant]
US 8465785B2 · Anfinsen et al. · 2013 [cited by applicant]
US 8859701B2 · Loick et al. · 2014 [cited by applicant]
US 9457048B2 · Davis et al. · 2016 [cited by applicant]
US 9492473B2 · von Maltzahn et al. · 2016 [cited by applicant]
US 9855294B2 · Heshmati et al. · 2018 [cited by applicant]
US 9867847B2 · Davis et al. · 2018 [cited by applicant]
US 9901595B2 · von Maltzahn et al. · 2018 [cited by applicant]
US 10172374B2 · Makita et al. · 2019 [cited by applicant]
US 10272155B2 · Elenko et al. · 2019 [cited by applicant]
US 10584183B2 · Sannino et al. · 2020 [cited by applicant]
US 10695363B2 · Rescigno et al. · 2020 [cited by applicant]
US 10953038B2 · Heshmati et al. · 2021 [cited by applicant]
US 20030224022A1 · Nussinovitch · 2003 [cited by applicant]
US 20050118326A1 · Anfinsen et al. · 2005 [cited by applicant]
US 20050250734A1 · Moreyra et al. · 2005 [cited by applicant]
US 20060093720A1 · Tatz · 2006 [cited by applicant]
US 20070104754A1 · Sterling et al. · 2007 [cited by applicant]
US 20120052151A1 · Sannino et al. · 2012 [cited by applicant]
US 20140276330A1 · Costa · 2014 [cited by applicant]
US 20150125568A1 · James · 2015 [cited by applicant]
US 20150196641A1 · Elenko et al. · 2015 [cited by applicant]
US 20150282510A1 · Makita et al. · 2015 [cited by applicant]
US 20150366898A1 · Heshmati et al. · 2015 [cited by applicant]
US 20150366989A1 · Liang et al. · 2015 [cited by applicant]
US 20160113953A1 · Gannedahl · 2016 [cited by applicant]
US 20160361351A1 · Davis et al. · 2016 [cited by applicant]
US 20170319616A1 · Lim · 2017 [cited by examiner]
US 20180289043A1 · Sannino et al. · 2018 [cited by applicant]
US 20190290675A1 · Gibson et al. · 2019 [cited by applicant]
US 20190373939A1 · Liu · 2019 [cited by applicant]
US 20200009168A1 · von Maltzahn et al. · 2020 [cited by applicant]
US 20200054572A1 · Matthiasson et al. · 2020 [cited by applicant]
US 20200165406A1 · Fitzpatrick et al. · 2020 [cited by applicant]
US 20210000896A1 · Mazoyer et al. · 2021 [cited by applicant]
US 20210038871A1 · Zhao et al. · 2021 [cited by applicant]
US 20210113596A1 · von Maltzahn et al. · 2021 [cited by applicant]
JP H09234004A · 1997 [cited by applicant]
JP 2003518008A · 2003 [cited by applicant]
JP 2005185211A · 2005 [cited by applicant]
JP 2012080806A · 2012 [cited by applicant]
WO 20010001950A1 · 2001 [cited by applicant]
WO 20010087365A2 · 2001 [cited by applicant]
WO 2004022074A1 · 2004 [cited by applicant]
WO 2005036971A1 · 2005 [cited by applicant]
WO 2010059725A1 · 2010 [cited by applicant]
WO 2014202997A2 · 2014 [cited by applicant]
WO 2015011988A1 · 2015 [cited by applicant]
WO 2015196054A1 · 2015 [cited by applicant]
WO 2016085322A1 · 2016 [cited by applicant]
WO 2018106845A1 · 2018 [cited by applicant]
USPTO; International Search Report and Written Opinion issued in Application No. PCT/US19/46077; dated Nov. 13, 2019; 10 pages. [cited by applicant]
Ni, et al.; “The Control of Ice Crystal Growth and Effect on Porous Structure of Konjac Glucomannan-Based Aerogels”; International Journal of Biologial Macromolecules; 2016; vol. 92; pp. 1130-1135. [cited by applicant]
Takei, et al.; “Autoclavable physically-crosslinked chitosan cryogel as a wound dressing”; Journal of Bioscience and Bioengineering; 2017; vol. 125; No. 4; pp. 490-495. [cited by applicant]
“Gelesis 100 Reduces Insulin Resistance in GLOW Obesity Trial;” Webpage located at: https://medtech.pharmaintelligence.informa.com/MT124859/Gelesis100-Reduces-Insulin-Resistance-in-GLOW-Obesity-Trial; accessed on Mar. 2… [cited by applicant]
“Gelesis Presents Pre-Clinical Data Suggesting Proprietary Hydrogel (GS300 Prototype) Reverses the Damage to the Intestines Induced by a High Fat Diet;” Website located at: https://www.gelesis.com/2020/11/13/gelesis-pre… [cited by applicant]
“Puretech Big-Gelesis (Proprietary Hydrogel Technology) (PLENITY, Gelesis200, GS300, GS400, GS500);” Webpage located at: https://puretech.red-hill.com/puretech-pipeline/details/hydrogel-platform-technology-for-gi-relate… [cited by applicant]
“Puretech Big-Giving Life to Science;” Webpage located at: https://puretechhealth.com/programs/details/gelesis-product-candidates; accessed on May 20, 2021. [cited by applicant]
Albillos et al., “The gut-liver axis in liver disease: Pathophysiological basis for therapy,” J. Hepatol. 2020, 72, 558-77. [cited by applicant]
Bu et al., “The hydration mechanism and hydrogen bonding structure of 6-carboxylate chitooligosaccharides superabsorbent material prepared by laccase/TEMPO oxidation system,” Carbohydr. Polym. 2018, 188, 151-158. [cited by applicant]
Entry for Agar, emedicinehealth.com 2016. [cited by applicant]
Functional Food Processing Technology, 1st ed.; Shimin Li ed.; China Light Industry Press, 2003; pp. 18-20. [cited by applicant]
Guo et al., “Effects of superabsorbent polymers on the abundances of antibiotic resistance genes, mobile genetic elements, and the bacterial community during swine manure composting,” Bioresour. Technol. 2017, 244 (Pt 1… [cited by applicant]
Klop et al., “Dyslipidemia in obesity: mechanisms and potential targets,” Nutrients 2013, 5, 1218-40. [cited by applicant]
Liu et al., “Ingestible hydrogel device,” Nat. Commun. 2019, 10, 493. [cited by applicant]
Rhim et al., “Mechanical and water barrier properties of agar/κ-carrageenan/konjac glucomannan ternary blend biohydrogel films,” Carbohydr. Polym. 2013, 96, 71-81. [cited by applicant]
Silverstri et al., “GELESIS Superabsorbent Hydrogel Prevents Hepatic Steatosis and Insulin Resistance in High Fat Diet-Induced NAFLD Pre-Clinical Model;” In The International Liver Congress 2019 (EASL 2019); Vienna, Aus… [cited by applicant]
Takei et al., “Autoclavable physically-crosslinked chitosan cryogel as a wound dressing,” J. Biosci. Bioeng. 2018, 125, 490-5. [cited by applicant]
Ni et al., “The control of ice crystal growth and effect on porous structure of konjac glucomannan-based aerogels,” Int. J. Biol. Macromol. 2016, 92, 1130-5. [cited by applicant]